1
|
Khan R, Kuenzig E, Tang A, Im J, Widdifield J, McCurdy J, Kaplan G, Benchimol E. A177 RISK OF VENOUS THROMBOEMBOLISM IN COVID-19 PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED MATCHED COHORT STUDY. J Can Assoc Gastroenterol 2023. [PMCID: PMC9991269 DOI: 10.1093/jcag/gwac036.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/09/2023] Open
Abstract
Background Venous thromboembolism (VTE), is associated with significant morbidity and mortality. Inflammation increases the risk of VTE, and it is a well-recognised complication of both inflammatory bowel disease (IBD) and COVID-19. Purpose To compare the risk of VTE among individuals with and without IBD following a positive COVID-19 test. Method Using health administrative data from Ontario, Canada we conducted a retrospective matched cohort study.All Ontario residents with a positive SARS-CoV-2 PCR test between January 1,2020 and December 30,2021 who had been diagnosed with IBD prior to their COVID-19 infection (identified using a validated algorithm) were matched to 5 individuals without IBD based on year of birth, sex, mean neighbourhood income quintile, date of positive COVID-19 test, and rural/urban residence. Individuals with a cancer diagnosis in the 5 years prior to their first COVID-19 positive test were excluded. Individuals were followed from positive COVID-19 PCR test until VTE event, death, migration out of Ontario or March 31, 2022.VTEs were identified from emergency department or hospitalization data using ICD-10 codes. Incidence rate of VTEs among individuals with IBD were assessed at 1, 6 and 12 months. Proportional cause-specific hazards models compared the risk of VTEs in people with and without IBD, treating death as a competing risk and controlling for vaccination status (2nd dose ≥14 days prior to positive COVID-19 test) and a history of VTE (VTE in the 5 years prior to infection). Result(s) There were 4293 people with IBD (44% Crohn’s disease, mean age ±SD 46.1±17.2 y) matched to 20,207 with out IBD (mean age 45.3±16.8 y) with a positive SARS-CoV-2 PCR test. Within 1 month of a positive COVID-19 test, the crude incidence rate of VTE in individuals with IBD was 4.77(95%CI, 4.75-4.80) per 100,000 person-days compared to 8.25(95%CI, 8.20-8.30) per 100,000 among people without IBD.Within 6 months, these rates were 1.86(95%CI, 1.86-1.87) and 2.12(95%CI, 2.11-2.12) per 100,000 person-days among people with and without IBD, respectivley. Within 12 months, these rates were 1.59(95% CI, 1.58-1.59) and 1.42(95% CI, 1.42-1.42) per 100,000 person-days among people with and without IBD, respectively.After adjusting for vaccination status and history of VTE there was no difference in the risk of VTE for people with and without IBD (HR 1.08, 95%CI, 0.64 to 1.83). Conclusion(s) IBD patients with COVID-19 were not more likely to experience a VTE infection compared with the general popluation. The risk of VTE was highest soon after COVID-19 and declined thereafter. Please acknowledge all funding agencies by checking the applicable boxes below None Disclosure of Interest None Declared
Collapse
Affiliation(s)
- R Khan
- SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, The Hospital for Sick Children, University of Toronto,ICES
| | - E Kuenzig
- Child Health Evaluative Sciences, SickKids Research Institute
| | - A Tang
- Child Health Evaluative Sciences, SickKids Research Institute
| | - J Im
- Child Health Evaluative Sciences, SickKids Research Institute
| | - J Widdifield
- ICES,Institute of Health Policy, Management and Evaluation, University of Toronto
| | - J McCurdy
- Department of Medicine, University of Ottawa, Ottawa, Canada
| | - G Kaplan
- Department of Medicine and Community Health Sciences, University of Calgary, Toronto, Canada
| | - E Benchimol
- SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, The Hospital for Sick Children, University of Toronto,ICES,Child Health Evaluative Sciences, SickKids Research Institute,Institute of Health Policy, Management and Evaluation, University of Toronto
| |
Collapse
|
2
|
Kuriya B, Eder L, Widdifield J, Ferreira-Legere L, Jeong IJ, Fang J, Chu A, Udell J. POS1406 EVALUATING THE QUALITY OF CARE FOR HEART FAILURE HOSPITALIZATIONS IN INFLAMMATORY ARTHRITIS- A POPULATION-BASED COHORT STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundIndividuals with inflammatory arthritis (IA) have an increased risk of heart failure (HF). Little is known if the quality of HF care differs among patients with IA compared to other chronic diseases such as diabetes mellitus (DM).ObjectivesWe examined adherence to quality-of-care indicators for HF hospitalizations among patients with IA compared to those with DM but no IA and the general population (without IA or DM).MethodsWe linked multiple population-based health datasets to construct a cohort of adults living in Ontario, Canada on January 1, 2011 and followed to December 2020. The IA cohort was identified using validated case definitions and included patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Comparison cohorts included adults with DM but no IA and general comparators without DM or IA. We included all subjects with a first HF hospitalization and who were alive at the time of discharge. We summarized the percentage of subjects in each of the 3 exposure groups who achieved recommended quality process measures [1]: (1) % receiving echocardiogram, (2) % receiving electrocardiogram, (3) % receiving a chest x-ray; and (4) % seen by a physician within 7 days of discharge. For those over the age of 65 years in whom medication information was universally available, we examined how many were dispensed evidence-based therapies: (5) % prescribed β-blocker, (6) % prescribed angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, (7) % prescribed mineralocorticoid receptor antagonist. We categorized adherence as perfect, moderate, or poor based on the number of measures achieved and compared proportions using pair-wise chi-squared tests.ResultsA first HF hospitalization occurred in 5,836 IA patients, 33,553 DM patients and 62,256 general comparators. The crude incidence rate for HF in IA was 2.70 per 1000/PY and was significantly higher compared to the general population (0.84 per 1000/PY), but lower compared to the DM cohort (5.01 per 1000/PY, p< 0.001). Mean age at time of HF hospitalization was significantly higher in the IA group (78 years) with more females affected (58%) compared to either the DM or general population group (p<0.001). All groups had high achievement of testing process measures and there were no differences in perfect adherence between the IA vs. DM and IA vs. general population comparators (Table 1). For those >65 years of age, patients with IA were less likely to achieve perfect adherence for medication quality indicators compared to either the DM or general population.Table 1.Percentage in each of three exposure groups achieving the recommended HF quality measures.Process MeasureIA GroupDM GroupGeneral Population1.Echocardiogram90.6%91.1%89.5%2.Electrocardiogram97.4%97.4%97.3%3.Chest x-ray99.7%99.6%99.6%4.Health care provider visit within 7 days of discharge39.0%38.9%38.7%Perfect Adherence (achieving 1, 2,3 and 4 above)33.0%33.0% (p=0.43, IA vs. DM)32.2% (p=0.15, IA vs general population)5.Beta-blocker prescribed64.8%70.5%66.6%6.Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker prescribed54.8%61.3%56.2%7.Mineralocorticoid receptor antagonist prescribed20.3%19.9%21.2%Perfect Adherence (achieving 5, 6 and 7 above)10.6%12.0% (p=<0.001, IA vs. DM)12.0% (p=0.02, IA vs general population)ConclusionHF quality indicators are adhered to in a high proportion of patients with IA following HF hospitalization. However, reasons for lower HF medication prescribing in IA compared to other high-risk conditions, such as DM, requires further evaluation. It will also be important to determine if adherence to HF quality of care translates to reduced long-term outcomes such as repeat HF hospitalizations and cardiovascular mortality, which we are currently exploring.References[1]Ontario HQ. Recommendations for Adoption: Heart Failure Care in the Community 2019 [Available from: http://www.hqontario.ca/Evidence-to-Improve-Care/Quality-StandardsDisclosure of InterestsBindee Kuriya Speakers bureau: Abbvie, Gilead, Pfizer, Lihi Eder Speakers bureau: Abbvie, UCB, Pfizer, Eli Lily, Novartis and Sandoz, Jessica Widdifield: None declared, Laura Ferreira-Legere: None declared, Irene JH Jeong: None declared, Jiming Fang: None declared, Anna Chu: None declared, Jacob Udell: None declared
Collapse
|
3
|
Tarannum S, Widdifield J, Wu F, Johnson S, Rochon P, Eder L. POS0159 SEX-RELATED DISPARITIES IN HEALTHCARE UTILIZATION IN PATIENTS WITH INFLAMMATORY ARTHRITIS: A POPULATION-BASED STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundDelayed diagnosis of inflammatory arthritis (IA) such as rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) is associated with joint damage and disability. So regular timely assessment by both family physicians and specialists is necessary for favorable disease outcomes. Sex (biology) and gender (socio-cultural) related factors influence clinical patterns of IA, patient behavior and their interaction with care providers. This influence could be reflected in patterns of healthcare utilization.ObjectivesTo compare patterns of musculoskeletal (MSK)-related healthcare utilization before and after diagnosis between male and female patients with IA in Ontario, Canada.MethodsWe assembled 3 inception cohorts of adult RA, AS and PsA patients diagnosed between April 2010 and March 2017 using Ontario health administrative data. MSK-related healthcare utilization patterns in terms of visits to physicians, MSK imaging and laboratory tests were assessed yearly for 3 years before and after the diagnosis date, and compared between male and female patients. Among individuals ≥ 66 years, prescriptions for rheumatic drugs (NSAIDs, corticosteroids, csDMARDs, advanced therapy (bDMARDs and tsDMARDs)) and opioids were ascertained. Regression models were used to compare healthcare utilization indicators between males and females after adjusting for demographics and comorbidities.ResultsA total of 41,277 patients with RA (69% females), 8,150 patients with AS (51% females) and 6,446 patients with PsA (54% female) were analyzed. Male patients were significantly older than female patients only in the RA cohort (mean age M 60.4 y, F 57.1 y). Multimorbidity, depression and osteoporosis were more common in female patients and cardiovascular disease in male patients across the 3 cohorts.Similar trends of sex-related differences were observed in all three cohorts. Female patients were more likely to visit rheumatologists and family physicians than male patients especially in earlier pre-diagnosis periods (Figure 1). Male patients were more likely to visit emergency department immediately before diagnosis. A similar female predominance was observed in imaging modalities of X-rays and ultrasounds (adjusted ORs for F:M 1.15 - 1.2 for X-rays and 1.07 -1.44 for ultrasounds), and laboratory tests before diagnosis (adjusted ORs for F:M 1.10 to 2.17) across the three cohorts.Overall DMARD prescription patterns in older male and female patients were similar across the three cohorts except more csDMARD prescriptions in female AS patients (Table 1). Female RA patients were more likely to use NSAIDs and opioids.Table 1.Odds ratios for prescription patterns in inflammatory arthritis for older female to male patients after diagnosisMedication ClassAdjusted Odds Ratio (95% Confidence Interval)Rheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritiscsDMARDYr 11.00 (0.92, 1.09)1.82 (1.38, 2.41)1.05 (0.81, 1.37)Yr 21.00 (0.92, 1.08)1.66 (1.24, 2.22)0.94 (0.73, 1.20)Yr 31.05 (0.97, 1.14)1.51 (1.12, 2.04)0.85 (0.66, 1.09)Advanced therapyYr 10.99 (0.78, 1.25)0.79 (0.49, 1.25)0.75 (0.47, 1.19)Yr 21.17 (0.99, 1.39)0.80 (0.53, 1.23)0.91 (0.61, 1.37)Yr 31.23 (1.05, 1.45)1.04 (0.67, 1.61)0.88 (0.6, 1.30)NSAIDYr 11.14 (1.04, 1.25)1.22 (0.91, 1.63)0.94 (0.71, 1.24)Yr 21.1 (0.99, 1.22)1.04 (0.77, 1.43)0.98 (0.73, 1.32)Yr 31.16 (1.04, 1.30)1.35 (0.96, 1.89)1.02 (0.73, 1.41)OpioidYr 11.39 (1.22, 1.58)1.23 (0.85, 1.78)1.32 (0.87, 1.98)Yr 21.51 (1.32, 1.72)1.22 (0.85, 1.76)1.14 (0.75, 1.75)Yr 31.46 (1.27, 1.68)1.42 (0.96, 2.09)1.45 (0.95, 2.23)Bolded results are statistically significant (p < 0.05). Odds ratios for female to male patients adjusted for age, residence, income quintiles, comorbidities and access to rheumatologistsConclusionFemale patients with IA have higher MSK-related healthcare utilization which may indicate biological differences in disease course or sociocultural differences in healthcare seeking behavior between male and female patients.ReferencesN/AAcknowledgementsDr. Sanjana Tarannum received funds from the Enid Walker Graduate Student Award for Research in Women’s Health for this study.Dr. Widdifield receives support from the Arthritis Society Stars Career Development Award (STAR-19-0610).Dr. Johnson has been awarded a Canadian Institutes of Health Research New Investigator Award.Dr. Paula Rochon holds the RTOERO Chair in Geriatric Medicine at the University of Toronto.Dr. Lihi Eder has been awarded Early Researcher Award from the Ontario Ministry of Research, Innovation and Science and Canada Research Chair (Tier 2) in Inflammatory Rheumatic Diseases.Disclosure of InterestsSanjana Tarannum: None declared, Jessica Widdifield: None declared, Fangyun Wu: None declared, Sindhu Johnson: None declared, Paula Rochon: None declared, Lihi Eder Grant/research support from: UCB, Abbvie, Pfizer, Janssen, Novartis, Eli Lily, SandozAdvisory board: Abbvie, Pfizer, Janssen, Novartis, Eli Lily
Collapse
|
4
|
Eder L, Croxford R, Drucker A, Mendel A, Bindee K, Touma Z, Johnson S, Cook R, Bernatsky S, Haroon N, Widdifield J. POS0050 ARE PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) MORE LIKELY TO RECEIVE COVID-19 TESTS AND TEST POSITIVE FOR SARS-COV-2? A MATCHED POPULATION-BASED STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Population-based data about the COVID-19 risk in patients with IMID remain scarce.Objectives:To investigate the cumulative incidence and risk factors for laboratory-confirmed COVID-19 infection and SARS-CoV2 testing in patients with IMID compared with matched non-IMID patients from the general population.Methods:A population-based, matched cohort study was conducted using health administrative data from adults living in Ontario, Canada from January to December 2020. Cohorts for each of the following IMID were assembled: rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, ankylosing spondylitis, systemic autoimmune rheumatic diseases (including lupus, systemic sclerosis, Sjogren’s, inflammatory myositis), multiple sclerosis (MS), iritis, inflammatory bowel disease (IBD), polymyalgia rheumatica (PMR) and vasculitis. Each patient was matched with 5 non-IMID comparators based on age, sex, area of residence and living in long term care (LTC). Standardized cumulative rates of testing for SARS-CoV2, and for receiving a positive test between IMID and non-IMID were compared between IMID and non-IMID patients. Multivariable logistic regression analyses assessed sociodemographic factors associated with COVID-19 testing and positivity.Results:A total of 493,499 IMID patients and 2,466,946 non-IMID comparators were assessed. Significantly more IMID patients versus non-IMID were tested for SARS-CoV2 (27.4% vs. 22.7%), while the proportions of those positive for COVID-19 were identical (0.9% of all patients in both groups). Overall, IMID patients were more likely to undergo SARS-CoV2 testing (odds ratio (OR) 1.28, 95% CI 1.27, 1.29), but their overall risk of laboratory-confirmed COVID-19 was not elevated (OR 0.97 (95% CI 0.93, 1)). However, the risk of laboratory-confirmed COVID-19 infection was lower in IBD (OR 0.75), MS (OR 0.77) and psoriasis (OR 0.94) and marginally higher in RA (OR 1.07) and iritis (OR 1.13) compared with non-IMID comparators (Figure 1A). The highest standardized rates of COVID-19 infection were found in vasculitis (115 per 10,000 patients) and iritis (109 per 10,000 patients) (Figure 1B). Risk factors for COVID-19 infection included younger age, living in LTC, multimorbidity, urban living and lower income (Table 1).Conclusion:Patients across all IMID were more likely to be tested for COVID-19 versus non-IMID patients. IMID patients were not at higher risk for testing positive for COVID-19 as an overall group, yet risk varied across disease subgroups.Table 1.Factors associated with COVID-19 infection in IMID vs. Non-IMID – Multivariable Logistic RegressionVariableORCI 95%IMID vs. Non-IMID0.970.93, 1.00Age (10-year increase)0.890.89, 0.90Sex: Female vs. Males0.950.93, 0.97LTC18.6417.9, 19.42ADG score:•5-9 vs. 0-41.401.35, 1.45•10-14 vs. 0-41.731.67, 1.80•15+ vs. 0-41.181.13, 1.23Urban vs. Rural3.493.26, 3.72Income quintile•Quintile 2 vs. 10.920.89, 0.96•Quintile 3 vs. 10.900.86, 0.93•Quintile 4 vs. 10.730.70, 0.76•Quintile 5 vs. 10.600.58, 0.63ADG - Aggregated Diagnosis Groups; IMIDs – Immune medicated inflammatory disease; LTC – long term careAcknowledgements:The study is supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Parts of this material are based on data and information compiled and provided by MOHLTC and the Canadian Institute for Health Information. The opinions, results and conclusions reported in this paper are those of the authors and are independent of the funding or data sources; no endorsement is intended or should be inferred.Disclosure of Interests:None declared.
Collapse
|
5
|
Eder L, Croxford R, Drucker A, Mendel A, Bindee K, Touma Z, Cook R, Johnson S, Bernatsky S, Haroon N, Widdifield J. OP0285 COVID-19 HOSPITALIZATIONS, ICU ADMISSION, AND DEATH AMONG PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) – A POPULATION-BASED STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1466] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:It remains unclear whether patients with IMID are at greater risk for severe COVID-19.Objectives:To investigate the risk of COVID-19 hospitalizations and their outcomes in patients with IMID compared with matched non-IMID patents from the general population.Methods:A population-based, matched cohort study was conducted in adults living in Ontario, Canada using health administrative data. Ten cohorts of the following IMID were assembled: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, systemic autoimmune rheumatic diseases (SARDs, including systemic lupus, systemic sclerosis, Sjogren’s, myositis), multiple sclerosis (MS), iritis, inflammatory bowel disease, polymyalgia rheumatica (PMR), and vasculitis (including giant cell arteritis and other types of vasculitidies). Each patient was matched with 5 non-IMID comparators based on age, sex, area of residence and living in long-term care (LTC). Patients who were admitted to hospital from January 1st to July 31th, 2020 and had ICD-10 COVID-19 diagnosis codes (U07.2 or U07.1) were identified. Among those with COVID-19 hospitalizations, we determined those with admissions to intensive care unit or required mechanical ventilation or died in hospital (‘complicated hospitalization’). Age-sex-standardized rates were compared between IMID and non-IMID patients and risk factors for hospitalizations were identified by multivariable logistic regression analysis.Results:In total, 493,499 IMID (417 hospitalized) and 2,466,946 non-IMID patients (1,519 hospitalized) were assessed. The age-sex-standardized rate of COVID-19 hospitalization was higher in IMID (6.4 per 10,000, 95% confidence interval (CI) 5.8, 7.2) versus non-IMID patients (4.8 per 100,000, 95% CI 4.5, 5). The highest rates of hospitalizations were found in vasculitis (18/10,000), MS (16.7/10,000) and PMR (10.1/10,000). IMID diagnosis was associated with 37% higher risk of being hospitalized for COVID-19 (Odds Ratio (OR) 1.37, 95% CI 1.23, 1.53) (Figure 1). This risk was slightly attenuated after adjusting for sociodemographic factors and comorbidities but remained elevated by 23% compared to non-IMID (OR 1.23, 95% CI 1.10, 1.37). The risk for hospitalizations was increased in RA, vasculitis, SARDs, PsA, MS and iritis (Figure 1). Risk factors for COVID-19 hospitalizations included older age, male sex, lower income, multimorbidity and living in long-term care (Table 1). The risk for complicated COVID-19 hospitalizations was higher by 21% in IMID patients (OR 1.21, 95% CI 1.02, 1.43), however, this association was attenuated after adjustment for demographics and comorbidities (OR 1.08).Table 1.Risk Factors for COVID-19 Hospitalizations in IMIDs vs. non-IMIDsVariableOR95% CIIMIDs vs. Non-IMID1.231.10, 1.37Age (10 yrs)1.491.44, 1.54Sex: Female0.680.62, 0.75Long term care resident8.287.32, 9.37ADG: 5-9 vs. 0-41.451.22, 1.7110-14 vs. 0-42.261.92, 2.6715+ vs. 0-43.232.73, 3.82Income (quintile) Quintile 2 vs. 10.820.73, 0.93 Quintile 3 vs. 10.760.67, 0.86 Quintile 4 vs. 10.560.48, 0.64 Quintile 5 vs. 10.460.40, 0.54Urban vs. rural4.333.32, 5.67ADG - Aggregated Diagnosis GroupsConclusion:Patients with IMID were at higher risk of being hospitalized with COVID-19 and for having complicated hospitalizations. Hospitalization risk was partially independent of their comorbid conditions.Acknowledgements:The study is supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Parts of this material are based on data and information compiled and provided by MOHLTC and the Canadian Institute for Health Information. The opinions, results and conclusions reported in this paper are those of the authors and are independent of the funding or data sources; no endorsement is intended or should be inferred.Disclosure of Interests:None declared
Collapse
|
6
|
Barra L, Pope J, Pequeno P, Gatley J, Widdifield J. SAT0252 INCREASED MORTALITY FOR INDIVIDUALS WITH GIANT CELL ARTERITIS: A POPULATION-BASED STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Individuals with giant cell arteritis (GCA) are at increased risk of serious morbidity including cardiovascular disease and stroke. Yet the risk of mortality among individuals with GCA have produced conflicting reports1.Objectives:Our aim was to evaluate excess all-cause mortality among individuals with GCA relative to the general population over time.Methods:We performed a population-based study in Ontario, Canada, using health administrative data among all individuals 50 years and older. Individuals with GCA were identified using a validated case definition (81% PPV, 100% specificity). All Ontario residents aged 50 and above who do not have GCA served as the General Population comparators. Deaths occurring in each cohort each year were ascertained from vital statistics. Annual crude and age/sex standardized all-cause mortality rates were determined for individuals with and without GCA between 2000 and 2018. Standardized mortality ratios (SMRs) were calculated to measure relative excess mortality over time. Differences in mortality between sexes and ages were also evaluated.Results:Population denominators among individuals 50 years and older with GCA and the General Population increased over time with 12,792 GCA patients and 5,456,966 comparators by 2018. Annual standardized mortality rates among the comparators steadily declined over time and were significantly lower than GCA morality rates (Figure). Annual GCA mortality rates fluctuated between 42-61 deaths per 1000 population (with overlapping confidence intervals) during the same time period. SMRs for GCA ranged from 1.28 (95% CI 1.08,1.47) at the lowest in 2002 to 1.96 (95% CI 1.84, 2.07) at the highest in 2018. GCA mortality rates and SMRs were highest among males and younger age groups.Conclusion:Over a 19-year period, mortality has remained increased among GCA patients relative to the general population. GCA mortality rates were higher among males and more premature deaths were occurring at younger age groups. In our study, improvements to the relative excess mortality for GCA patients over time (mortality gap) did not occur. Understanding cause-specific mortality and other factors are necessary to inform contributors to premature mortality among GCA patients.References:[1]Hill CL, et al. Risk of mortality in patients with giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46(4):513-9.Figure.Acknowledgments: :This study was supported by a CIORA grantDisclosure of Interests:Lillian Barra: None declared, Janet Pope Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, Merck, Roche, Seattle Genetics, UCB, Consultant of: AbbVie, Actelion, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eicos Sciences, Eli Lilly & Company, Emerald, Gilead Sciences, Inc., Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Speakers bureau: UCB, Priscila Pequeno: None declared, Jodi Gatley: None declared, Jessica Widdifield: None declared
Collapse
|
7
|
Kassardjian CD, Widdifield J, Paterson JM, Kopp A, Nagamuthu C, Barnett C, Tu K, Breiner A. Serious infections in patients with myasthenia gravis: population‐based cohort study. Eur J Neurol 2020; 27:702-708. [DOI: 10.1111/ene.14153] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 01/09/2020] [Indexed: 11/29/2022]
Affiliation(s)
- C. D. Kassardjian
- Division of Neurology Department of Medicine St Michael's Hospital University of Toronto Toronto ON
| | - J. Widdifield
- Holland Bone & Joint Research Program Sunnybrook Health Sciences Centre Sunnybrook Research Institute Toronto ON
- Institute of Health Policy, Management & Evaluation University of Toronto Toronto ON
- ICES Toronto ON
| | - J. M. Paterson
- Institute of Health Policy, Management & Evaluation University of Toronto Toronto ON
- ICES Toronto ON
| | | | | | - C. Barnett
- Division of Neurology Department of Medicine Ellen and Martin Prosserman Centre for Neuromuscular Diseases University Health Network University of Toronto Toronto ON
| | - K. Tu
- Department of Community and Family Medicine North York General Hospital University Health Network Toronto ON
| | - A. Breiner
- Division of Neurology Department of Medicine The Ottawa Hospital and Ottawa Hospital Research Institute Ottawa ON Canada
| |
Collapse
|
8
|
Widdifield J, Abrahamowicz M, Paterson M, Bombardier C, Tomlinson G, Huang A, Kuriya B, Bernatsky S. THU0348 The Influence of Drug Exposures and Comorbidity on Survival in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
9
|
Widdifield J, Bernatsky S, Paterson M, Abrahamowicz M, Kuriya B, Tomlinson G, Tatangelo M, Thorne C, Pope J, Luo J, Bombardier C. SAT0347 Comparisons of Reporting and Level of Agreement of Co-Morbidities Ascertained from Rheumatologists, Patients and Health Administrative Data: A Data Linkage Study Among Patients with Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
10
|
Cui K, Jacob B, Widdifield J, Pope J, Kuriya B, Akhavan P, Bombardier C. SAT0119 Prevalence of Cardiovascular Disease and its Associations with Disease Severity in Rheumatoid Arthritis Patients – Data from the Ontario Best Practices Research Initiative (OBRI). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
11
|
Widdifield J, Moura C, Wang Y, Abrahamowicz M, Beauchamp ME, Paterson M, Huang A, Boire G, Fortin P, Bessette L, Bombardier C, Hanly J, Feldman D, Bernatsky S. OP0020 The Influence of Drug Exposures on Joint Surgeries in Rheumatoid Arthritis Patients: Cross-Provincial Comparisons. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
12
|
Widdifield J, Young J, Bombardier C, Jaakkimainen R, Butt D, Ivers N, Bernatsky S, Paterson J, Thorne J, Ahluwalia V, Tomlinson G, Tu K. FRI0194 Identifying Patients with Rheumatoid Arthritis in Primary Care Electronic Medical Records. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4816] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
13
|
Moura C, Abrahamowicz M, Beauchamp ME, Lacaille D, Wang Y, Bombardier C, Widdifield J, Hanly J, Boire G, Feldman D, Maksymowych W, Peschken C, Barnabe C, Edworthy S, Fortin P, Bessette L, Behlouli H, Bernatsky S. THU0120 Is Early DMARD Use Associated with Less Joint Replacement Surgery? an Analysis of 5,199 Incident Rheumatoid Arthritis (RA) Patients. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Widdifield J, Paterson JM, Bernatsky S, Tu K, Thorne JC, Bombardier C. FRI0518 Epidemiology of rheumatoid arthritis in a universal public health care system: results from the ontario ra administrative database (ORAD). Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1645] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
15
|
Widdifield J, Bernatsky S, Paterson J, Thorne J, Tu K, Bombardier C. FRI0410 Rheumatoid arthritis (RA) care: Geographic disparities and impact of primary care physicians on access to rheumatologists. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|